Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBYND6)

• Drug Name: leucettine L41 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 135398522
  TTD Drug ID: DMBYND6

Molecule-Related Drug Atlas

Drug(s) Targeting CDC-like kinase 3 (CLK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
KH-CB19	DMSOB3U	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting Dual-specificity tyrosine-phosphorylation regulated kinase 2 (DYRK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Harmine	DMPA5WD	Discovery agent	N.A.	Patented	[4]
PMID28766366-Compound-Scheme21Left	DMWTRUK	N. A.	N. A.	Patented	[4]
PMID28766366-Compound-Scheme21Right	DMF3X40	N. A.	N. A.	Patented	[4]
PMID28766366-Compound-Scheme14BINDY	DMBQ0RN	N. A.	N. A.	Patented	[4]
PMID28766366-Compound-Scheme16DMAT	DMQ5UEA	N. A.	N. A.	Patented	[4]

Drug(s) Targeting CDC-like kinase 1 (CLK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TG003	DMP4HR2	Discovery agent	N.A.	Patented	[5]
PMID23642479C17	DM4JWMA	Discovery agent	N.A.	Investigative	[6]
ML315	DMNOREK	Discovery agent	N.A.	Investigative	[6]
KH-CB19	DMSOB3U	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting Serine/threonine-protein kinase pim-1 (PIM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SEL-24	DMH064K	Acute myeloid leukaemia	2A60	Phase 1/2	[7]
CXR-1002	DM4GJ50	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
Benzothiazine derivative 1	DMMVHY4	N. A.	N. A.	Patented	[9]
PMID21982499C14k	DM0VOXN	Discovery agent	N.A.	Investigative	[10]
PMID22136433C20	DMI8217	Discovery agent	N.A.	Investigative	[11]
NCGC00167772-01	DMY8RT9	Discovery agent	N.A.	Investigative	[7]
SMI-4a	DMBLWMS	Non-small-cell lung cancer	2C25	Investigative	[12]

Drug(s) Targeting Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Harmine	DMPA5WD	Discovery agent	N.A.	Patented	[4]
PMID28766366-Compound-Scheme21Left	DMWTRUK	N. A.	N. A.	Patented	[4]
PMID28766366-Compound-Scheme21Right	DMF3X40	N. A.	N. A.	Patented	[4]
PMID28766366-Compound-Scheme14BINDY	DMBQ0RN	N. A.	N. A.	Patented	[4]
TG003	DMP4HR2	Discovery agent	N.A.	Patented	[4]
PMID28766366-Compound-Scheme2WO2012/098065bottom	DMO4Q95	N. A.	N. A.	Patented	[4]
PMID28766366-Compound-Scheme16DMAT	DMQ5UEA	N. A.	N. A.	Patented	[4]
PMID28766366-Compound-Scheme7WO2012/098070upper	DMGAQR5	N. A.	N. A.	Patented	[4]
PMID28766366-Compound-Scheme9EHT1610	DMMZGC8	N. A.	N. A.	Patented	[4]
PMID28766366-Compound-Scheme9EHT5372	DM0O18N	N. A.	N. A.	Patented	[4]

Drug(s) Affected By Serine/arginine-rich splicing factor 4 (SRSF4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[13]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[13]
Dihydroartemisinin	DMBXVMZ	Malaria	1F40-1F45	Approved	[14]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[15]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[16]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[17]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[18]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[19]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[20]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[20]

Drug(s) Affected By Serine/arginine-rich splicing factor 6 (SRSF6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[21]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[22]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[23]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[24]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[25]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[16]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[26]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[27]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[28]
Indomethacin	DMSC4A7	Bursitis		Approved	[29]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
CDC-like kinase 1 (CLK1)	TTE6YDG	CLK1_HUMAN	Inhibitor	[1]
CDC-like kinase 3 (CLK3)	TTQPE1U	CLK3_HUMAN	Inhibitor	[1]
Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)	TTSBVFO	DYR1A_HUMAN	Inhibitor	[1]
Dual-specificity tyrosine-phosphorylation regulated kinase 2 (DYRK2)	TT84OS6	DYRK2_HUMAN	Inhibitor	[1]
Dual-specificity tyrosine-phosphorylation regulated kinase 4 (DYRK4)	TTCLIHJ	DYRK4_HUMAN	Inhibitor	[2]
Serine/threonine-protein kinase pim-1 (PIM1)	TTTN5QW	PIM1_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Serine/arginine-rich splicing factor 4 (SRSF4)	OTLI7CU1	SRSF4_HUMAN	Post-Translational Modifications	[1]
Serine/arginine-rich splicing factor 6 (SRSF6)	OTGLOSYE	SRSF6_HUMAN	Post-Translational Modifications	[1]

References

• [1] Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem. 2011 Jun 23;54(12):4172-86.
• [2] Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. J Med Chem. 2012 Nov 8;55(21):9312-30.
• [3] Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. 2011 Jan 28;18(1):67-76.
• [4] Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
• [5] A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
• [6] Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2158).
• [8] 123 Antitumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action. EJC Supplements, 2010; 8(7):45-46.
• [9] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
• [10] 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorg Med Chem Lett. 2011 Nov 15;21(22):6687-92.
• [11] 7,8-dichloro-1-oxo-beta-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes. J Med Chem. 2012 Jan 12;55(1):403-13.
• [12] Pim-1 inhibitor SMI-4a suppresses tumor growth in non-small cell lung cancer via PI3K/AKT/mTOR pathway. Onco Targets Ther. 2019 Apr 23;12:3043-3050.
• [13] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [14] Untargeted Proteomics and Systems-Based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells. Chem Res Toxicol. 2015 Oct 19;28(10):1903-13. doi: 10.1021/acs.chemrestox.5b00105. Epub 2015 Sep 21.
• [15] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [16] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [17] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [18] Benzo[a]pyrene increases the Nrf2 content by downregulating the Keap1 message. Toxicol Sci. 2010 Aug;116(2):549-61.
• [19] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [20] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [21] Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood. 2007 May 15;109(10):4450-60.
• [22] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [23] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [24] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [25] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [26] Gene expression signatures after ethanol exposure in differentiating embryoid bodies. Toxicol In Vitro. 2018 Feb;46:66-76.
• [27] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [28] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [29] Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells. Neoplasia. 2006 Sep;8(9):758-71.